Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Woods

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
CJEM|June 30, 2023
Ready for practice? National recommendations for emergency medicine transition to practice curriculumTamara McColl, Quinten Paterson, Stella Yiu, et al.
The Journal of Biological Chemistry|July 15, 2017
Use of a neutralizing antibody helps identify structural features critical for binding of <i>Clostridium difficile</i> toxin TcdA to the host cell surfaceHeather K Kroh, Ramyavardhanee Chandrasekaran, Kim Rosenthal, et al.
Plos One|January 26, 2019
Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategyReena Varkey, Qun Du, Jodi L Karnell, et al.
The Journal of Biological Chemistry|November 29, 2017
A neutralizing antibody that blocks delivery of the enzymatic cargo of <i>Clostridium difficile</i> toxin TcdB into host cellsHeather K Kroh, Ramyavardhanee Chandrasekaran, Zhifen Zhang, et al.
Cellular & Molecular Immunology|May 6, 2015
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cellsAndrew C Nyborg, Anna Zacco, Rachel Ettinger, et al.
International Journal of Oncology|February 14, 2012
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft modelsChing Ching Leow, Karen Coffman, Ivan Inigo, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumorsElizabeth M Bruckheimer, Christine A Fazenbaker, Sandra Gallagher, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 22, 2016
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokineticsPamela Thompson, Ryan Fleming, Binyam Bezabeh, et al.
Mabs|September 28, 2017
Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptorsCaroline S Colley, Bojana Popovic, Sudharsan Sridharan, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 8, 2010
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibodyRonald Herbst, Yue Wang, Sandra Gallagher, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
CJEM|June 30, 2023
Ready for practice? National recommendations for emergency medicine transition to practice curriculumTamara McColl, Quinten Paterson, Stella Yiu, et al.
The Journal of Biological Chemistry|July 15, 2017
Use of a neutralizing antibody helps identify structural features critical for binding of <i>Clostridium difficile</i> toxin TcdA to the host cell surfaceHeather K Kroh, Ramyavardhanee Chandrasekaran, Kim Rosenthal, et al.
Plos One|January 26, 2019
Discovery and characterization of potent IL-21 neutralizing antibodies via a novel alternating antigen immunization and humanization strategyReena Varkey, Qun Du, Jodi L Karnell, et al.
The Journal of Biological Chemistry|November 29, 2017
A neutralizing antibody that blocks delivery of the enzymatic cargo of <i>Clostridium difficile</i> toxin TcdB into host cellsHeather K Kroh, Ramyavardhanee Chandrasekaran, Zhifen Zhang, et al.
Cellular & Molecular Immunology|May 6, 2015
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cellsAndrew C Nyborg, Anna Zacco, Rachel Ettinger, et al.
International Journal of Oncology|February 14, 2012
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft modelsChing Ching Leow, Karen Coffman, Ivan Inigo, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumorsElizabeth M Bruckheimer, Christine A Fazenbaker, Sandra Gallagher, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 22, 2016
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokineticsPamela Thompson, Ryan Fleming, Binyam Bezabeh, et al.
Mabs|September 28, 2017
Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptorsCaroline S Colley, Bojana Popovic, Sudharsan Sridharan, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 8, 2010
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibodyRonald Herbst, Yue Wang, Sandra Gallagher, et al.
Pageof 6